Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies episode artwork

EPISODE · Aug 5, 2024 · 47 MIN

Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies

from touchPODCAST · host touchpodcast

touchTALKS for touchNEUROLOGY A thrombosis and haemostasis expert shares insights into reversal strategies for patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH), including benefits and risks of DOAC use, evidence for DOAC reversal agents and guideline-directed management of the condition.  The expert Prof. Dr. med. Jan Beyer-Westendorf, University Hospital Carl Gustav Carus, Dresden, Germany This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: www.touchneurology.com

Episode metadata supplied by the publisher feed · Published Aug 5, 2024

Embed this episode

Ready to play

Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies

0:00 47:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 47 minutes long.

When was this touchPODCAST episode published?

This episode was published on August 5, 2024.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!